When patients with chronic kidney disease (CKD) and gout move from primary care to a kidney specialist, their gout flares actually get worse before they get better. New research presented at the National Kidney Foundation's 2026 Spring Clinical Meetings reveals that gout flare rates peak at 17.6% during the first six months of this transition, then decline significantly to 9.2% by the second half of year two. Understanding why this happens, and what it means for your kidney health, could help you navigate this critical period more smoothly.

Why Do Gout Flares Spike When Switching to a Kidney Specialist?

The spike in gout flares during the nephrology transition might seem counterintuitive, but it reflects a positive shift in care. When patients first see a nephrologist, several important changes happen simultaneously. Serum uric acid testing increases from 50.5% to 56.7%, and prescriptions for urate-lowering therapy (ULT), medications that reduce uric acid levels, jump from 68.4% to 71.3%. The average number of medications prescribed increases from 1.54 to 1.72.

"The transient increase in gout flares after referral to a nephrologist is often paradoxically due to this improved gout care. Starting or adjusting urate-lowering therapy such as allopurinol is known to temporarily trigger flares," explained Dr. Brian LaMoreaux of Amgen and colleagues.

Dr. Brian LaMoreaux, Amgen

This temporary worsening is actually a sign that treatment is working. When urate-lowering medications begin breaking down uric acid deposits in the body, they can trigger acute gout attacks as crystals mobilize and move through the bloodstream. It's an uncomfortable but expected part of the healing process.

What Happens After the First Six Months?

The good news is that this difficult period doesn't last. Once nephrology care becomes established and patients remain under specialist supervision, the pattern reverses dramatically. Emergency department visits for gout drop to 0.9% after the transition and hold steady at 0.8% for the next 1.5 to 2 years. This improvement reflects better disease control and more consistent monitoring.

The research examined data from 3,757 adult patients with an average age of 73 years, 64% of whom were men. Common comorbidities included hyperlipidemia (72%), hypertension (53%), and diabetes (51%). These conditions often coexist with both gout and kidney disease, making comprehensive care even more important.

How to Prepare for Your Transition to Nephrology Care

• Schedule a Pre-Visit Lab Check: Ask your primary care physician to check your baseline serum uric acid level before your first nephrology appointment. This gives your new specialist important baseline data and helps them plan your initial treatment strategy.
• Communicate Between Providers: Encourage direct communication between your primary care doctor and your nephrologist. A simple handoff conversation about your gout history, current medications, and treatment goals can smooth the transition and prevent gaps in care.
• Prepare for Temporary Flares: Understand that starting or adjusting urate-lowering therapy may trigger gout attacks in the first few months. This is normal and expected, not a sign that treatment is failing. Work with your nephrologist on a flare management plan.
• Increase Clinic Visit Frequency: Nephrologists typically see patients 3 to 4 times per year, compared with 1 to 2 times annually in primary care. More frequent monitoring allows for better medication adjustments and earlier detection of problems.

The Bigger Picture: Uncontrolled Gout and Kidney Disease Risk

The stakes of managing gout well during this transition are high. A separate analysis of 19,674 patients with uncontrolled gout and 24,885 with controlled gout found striking differences in kidney disease risk. Patients with uncontrolled gout faced a 2.1 times higher risk of developing stage 3 or higher CKD, a 3.5 times higher risk of end-stage kidney disease, and a 1.5 times higher risk of all-cause mortality compared with those whose gout was well-controlled.

"These findings further suggest the importance of adequately controlling serum urate levels with proactive monitoring for specific comorbidities in patients with uncontrolled gout," noted Dr. Brad Marder of Amgen.

Dr. Brad Marder, Amgen

This connection works both ways. Uncontrolled gout can cause kidney disease, and kidney disease makes gout harder to treat. Patients with both conditions face a particularly challenging situation. A real-world study of 146 patients with stage 3 or higher CKD and uncontrolled gout found that after nearly 19 months of treatment, their average serum uric acid remained dangerously high at 8.4 mg/dL (normal is below 6 mg/dL). Despite receiving an average of 1.9 different treatments, these patients continued experiencing an average of 2.3 gout flares per year.

The researchers noted that kidney disease-related contraindications and dose limitations, along with insurance formulary restrictions, constrained the available treatment options for these patients. This suggests that current therapies may not be sufficient for everyone, highlighting a genuine gap in treatment options for this vulnerable population.

What Experts Want You to Know About This Transition

The transition from primary care to nephrology is not just a routine referral. It's a critical moment where treatment intensifies, monitoring increases, and your disease management fundamentally changes. The temporary spike in gout flares during the first six months reflects this shift toward more aggressive, evidence-based care. The American College of Rheumatology recommends a "treat to target" strategy, meaning doctors should adjust medications until serum uric acid levels reach the goal of 6 mg/dL or lower.

For patients with both CKD and gout, this transition offers an opportunity to get your condition under control before it causes irreversible kidney damage. The key is understanding that the initial discomfort of increased flares is temporary and purposeful. By the second year of nephrology care, most patients experience significantly fewer flares and emergency visits, suggesting that the difficult transition period pays off in better long-term outcomes.